AstraZeneca Denies Unjust Enrichment In Cancer Drug Row

By Joanne Faulkner (September 3, 2021, 1:58 PM BST) -- AstraZeneca has doubled down on claims that it is owed unpaid royalties by U.S. drugmaker Tesaro from sales of a blockbuster cancer drug after the pharmaceutical giant was hit with a $3.6 million counterclaim.

AstraZeneca also denied in filing at the High Court dated Aug. 25 that it is entitled to royalties only on sales of the drug used for that specific type of cancer treatment — when it is used to treat so-called HRD cells — but not on other sales.

The Anglo-Swedish company has dismissed Tesaro's counterclaim, which says it is entitled to claw back $3.5 million in royalties that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!